DE69432299D1 - Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen - Google Patents

Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen

Info

Publication number
DE69432299D1
DE69432299D1 DE69432299T DE69432299T DE69432299D1 DE 69432299 D1 DE69432299 D1 DE 69432299D1 DE 69432299 T DE69432299 T DE 69432299T DE 69432299 T DE69432299 T DE 69432299T DE 69432299 D1 DE69432299 D1 DE 69432299D1
Authority
DE
Germany
Prior art keywords
treatment
conditions
botulinum toxins
neuromuscular disorders
multiple botulinum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69432299T
Other languages
English (en)
Other versions
DE69432299T2 (de
Inventor
Roger Aoki
W Grayston
R Carlson
M Leon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DE69432299D1 publication Critical patent/DE69432299D1/de
Publication of DE69432299T2 publication Critical patent/DE69432299T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69432299T 1993-06-10 1994-06-07 Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen Expired - Lifetime DE69432299T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7503293A 1993-06-10 1993-06-10
PCT/US1994/006418 WO1994028923A1 (en) 1993-06-10 1994-06-07 Multiple botulinum toxins for treating neuromuscular disorders and conditions

Publications (2)

Publication Number Publication Date
DE69432299D1 true DE69432299D1 (de) 2003-04-24
DE69432299T2 DE69432299T2 (de) 2003-12-11

Family

ID=22123106

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69432299T Expired - Lifetime DE69432299T2 (de) 1993-06-10 1994-06-07 Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen

Country Status (8)

Country Link
US (1) US20010021695A1 (de)
EP (1) EP0702559B1 (de)
JP (2) JP4249802B2 (de)
AU (1) AU683275B2 (de)
CA (1) CA2164626C (de)
DE (1) DE69432299T2 (de)
ES (1) ES2194025T3 (de)
WO (1) WO1994028923A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
WO1994000481A1 (en) * 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
EP1477183B1 (de) * 1993-12-28 2005-11-02 Allergan, Inc. Toxisches komponent der Botulinustoxine zur Modulation cholinergisch-kontrollierter Sekretionen
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US8187612B2 (en) 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
AU2007202480B2 (en) * 1993-12-28 2009-01-29 Allergan, Inc. Method for treating pain associated with a muscle disorder
US8557256B2 (en) 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
EP0773788B1 (de) * 1995-06-06 2003-05-07 L. Bruce Pearce Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen
DE69620888T2 (de) * 1996-11-27 2002-08-14 William J. Binder Neurotoxine zur Behandlung von Hauterkrankungen bei Säugetieren
US7470431B2 (en) 1997-07-15 2008-12-30 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer
US7449192B2 (en) 1997-07-15 2008-11-11 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
US9066943B2 (en) 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
US7455845B2 (en) 1997-07-15 2008-11-25 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
JP3692033B2 (ja) 1997-07-15 2005-09-07 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド 泌尿器疾患及び関連疾患の治療のための神経毒治療法の使用
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
EP1053014A4 (de) 1998-01-26 2004-11-10 Univ Massachusetts BIOLOGISCH AKTIVES HÄMAGGLUTININ VOM TYP A i(STRIDIUM BOTULINUM) UNDVERFAHREN ZU SEINER VERWENDUNG
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
BR9914891A (pt) 1998-10-27 2001-07-17 Mayo Foundation Processos para aperfeiçoamento de cura de ferimento
DE19856897A1 (de) * 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
DE10035156A1 (de) * 2000-07-19 2002-02-07 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
EP1611901B1 (de) * 2003-03-13 2013-07-10 Eisai R&D Management Co., Ltd. Mittel zur Prävention oder Heilung von Zähneknirschen
US8343929B2 (en) * 2004-09-23 2013-01-01 Toxcure, Inc. Treating neoplasms with neurotoxin
EP2298339B1 (de) * 2004-09-23 2015-07-15 Toxcure, Inc. Behandlung von Neoplasmen mit Neurotoxin
AU2006340711C1 (en) 2005-04-05 2013-02-07 Allergan, Inc. Clostridial toxin activity assays
US8105611B2 (en) * 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
FR2896693B1 (fr) * 2006-01-27 2008-03-14 Sod Conseils Rech Applic Composition comprenant plusieurs toxines botuliques
WO2009139739A1 (en) * 2006-02-14 2009-11-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions comprising a combination of botulinum toxin a and botulinum toxin b for treating conditions characterized by unwanted or excessive presynaptic neuronal activity or secretion
US20130171122A1 (en) * 2011-12-29 2013-07-04 Allergan, Inc. Endopeptidase and neurotoxin combination treatment of bladder disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
WO1994000481A1 (en) * 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex

Also Published As

Publication number Publication date
DE69432299T2 (de) 2003-12-11
US20010021695A1 (en) 2001-09-13
JPH08511537A (ja) 1996-12-03
EP0702559B1 (de) 2003-03-19
CA2164626C (en) 2004-11-23
EP0702559A1 (de) 1996-03-27
JP2006052227A (ja) 2006-02-23
AU683275B2 (en) 1997-11-06
ES2194025T3 (es) 2003-11-16
AU7101894A (en) 1995-01-03
JP4249802B2 (ja) 2009-04-08
CA2164626A1 (en) 1994-12-22
WO1994028923A1 (en) 1994-12-22

Similar Documents

Publication Publication Date Title
DE69432299D1 (de) Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen
DE69434540D1 (de) Neurotoxisches Komponente von Botulinumtoxinen zur Behandlung von zervikaler Dystonie
DE69435235D1 (de) Behandlung von neuromuskularen Störungen und Zuständen mit verschiedenen botulinen Serotypen
ATE275383T1 (de) Oxadisäuren und verwandte verbindungen zur behandlung von hautstörungen
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
DE69429369D1 (de) Verfahren und mittel zur behandlung abnormaler zustände des epitheliums von körperöffnungen
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
ATE331522T1 (de) Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum
DE69834693D1 (de) Zusammensetzung zur behandlung von elastischen polyurethanfasern und die damit behandelten fasern
ATE280577T1 (de) Oxa-säuren und verwandte verbindungen zur behandlung von störungen der haut
DE69014030D1 (de) Mittel für die Verhütung und Behandlung von Diarrhöe.
DE69024039D1 (de) Behandlung von pathologischen zuständen und krankheiten.
DE58902094D1 (de) Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.
ATA46794A (de) Einrichtung zur behandlung von hautzonen
ATA11989A (de) Mittel zur vorbeugung gegen und behandlung von parodontopathien
DE69421193D1 (de) Mittel und Verfahren zur Metallbehandlung
ATE178487T1 (de) Verwendung von 2-amino-4-(4-fluorbenzylamino)-1- ethoxycarbonylaminobenzen zur prophylaxe und behandlung der folgen der akuten und chronischen zerebralen minderdurchblutung sowie neurodegenerativer erkrankungen
DE59600709D1 (de) Adsorbens zur behandlung von ölen und/oder fetten
DE69422842D1 (de) Verfahren und Einrichtung zur Behandlung von Lithium
DE69532066D1 (de) Arzneimittel zur Behandlung von Restenosis und Gefässsklerose
DE69825319D1 (de) Präparat zur vorbeugung und behandlung von entzündungen
ATE264854T1 (de) Atropisomere 3-heteroaryl-4(3h)-chinazolinone zur behandlung von neurodegenerativen und cns-trauma zuständen
DE69900339D1 (de) Mittel und Verfahren zur Behandlung von Kunstfasern
DE69418931D1 (de) Verwendung von VIP und deren Analogen und Fragmenten zur Behandlung von neurodegenerativen Krankheiten
DE3686019D1 (de) Die verwendung von nitrofurantoin zur behandlung und verhuetung von magen-darmkrankheiten.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition